R(
Therapeutic Areas
Regeneron Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| EYLEA (aflibercept) | Neovascular (Wet) Age-related Macular Degeneration | Marketed |
| Dupixent (dupilumab) | Atopic Dermatitis, Asthma, CRSwNP, EoE | Marketed |
| Libtayo (cemiplimab) | Advanced Cutaneous Squamous Cell Carcinoma | Marketed |
| Fianlimab + Libtayo | Melanoma (1L adjuvant & advanced) | Phase 3 |
| Pozelimab | CHAPLE Disease | BLA Submitted |
| Odronextamab | Relapsed/Refractory Follicular Lymphoma & DLBCL | BLA Submitted |
| Garetosmab | Fibrodysplasia Ossificans Progressiva (FOP) | Phase 3 |
| REGN1908-1909 | Cat Allergy | Phase 3 |
Leadership Team at Regeneron Pharmaceuticals
LS
Leonard S. Schleifer
Founder, President and Chief Executive Officer
GD
George D. Yancopoulos
Founder, President and Chief Scientific Officer
MM
Marion McCourt
EVP, Head of Commercial
NS
Neil Stahl
EVP, Research and Development
C(
Christine (Chris) O'Brien
SVP, Head of Clinical Development
MS
Michael S. Brown
Scientific Advisor, Co-founder RGC
JL
Joseph L. Goldstein
Scientific Advisor, Co-founder RGC